Acceleron Pharma

412 articles about Acceleron Pharma

• Acceleron Pharma To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of American Society of Clinical Oncology

  5/15/2014

• Acceleron Pharma Reports First Quarter 2014 Financial Results

  5/15/2014

• Acceleron Pharma To Present At 2014 UBS Global Healthcare Conference

  5/12/2014

• Acceleron Pharma To Host First Quarter 2014 Financial Results Conference Call And Webcast On May 15, 2014

  5/8/2014

• Acceleron Pharma, Celgene Corporation And Collaborators Announce Two Publications In Nature Medicine Describing Sotatercept And ACE-536 Therapeutic Potential In Beta-Thalassemia And Myelodysplastic Syndromes

  3/24/2014

• Acceleron Pharma To Present At The 21st Annual Future Leaders In The Biotech Industry Conference

  3/20/2014

• Acceleron Pharma And Celgene Corporation Announce Interim Clinical Data For Sotatercept In Patients With End Stage Renal Disease On Hemodialysis At The 2014 National Kidney Foundation Spring Clinical Meeting

  3/18/2014

• Acceleron Pharma To Present At Cowen and Company 34th Annual Health Care Conference

  2/27/2014

• Acceleron Pharma Reports Fourth Quarter And Year Ended 2013 Financial Results

  2/26/2014

• Acceleron Pharma To Host Fourth Quarter And Year Ended 2013 Financial Results Conference Call And Webcast On February 26, 2014

  2/19/2014

• Acceleron Pharma To Present At 2014 Leerink Swann and Company Global Healthcare Conference

  2/5/2014

• Acceleron Pharma Announces Pricing Of Public Offering Of Common Stock

  1/23/2014

• Acceleron Pharma Commences Proposed Public Offering Of Common Stock

  1/21/2014

• Acceleron Pharma Files Registration Statement For Proposed Public Offering Of Common Stock

  1/10/2014

• Acceleron Pharma To Be Added To Russell 2000&#0174 Index

  12/20/2013

• Acceleron Pharma Earns $7 Million Milestone Payment For Celgene’s Initiation Of Sotatercept Phase 2 Clinical Trial In Patients With End Stage Renal Disease On Hemodialysis

  12/18/2013

• Acceleron Pharma And Celgene Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society of Hematology Annual Meeting

  12/9/2013

• Acceleron Pharma Provides Update On Clinical Pipeline At Piper Jaffray Healthcare Conference

  12/3/2013

• Acceleron Pharma Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society of Hematology Annual Meeting

  12/2/2013

• Acceleron Pharma to Present at Piper Jaffray Healthcare Conference in December

  11/25/2013